Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.

Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI.

J Clin Oncol. 2008 May 1;26(13):2147-54. doi: 10.1200/JCO.2007.15.0532. Epub 2008 Mar 24.

PMID:
18362364
2.

The evolving role of estrogen therapy in prostate cancer.

Oh WK.

Clin Prostate Cancer. 2002 Sep;1(2):81-9. Review.

PMID:
15046698
3.

Targeted therapies for prostate cancer against the prostate specific membrane antigen.

Elsässer-Beile U, Bühler P, Wolf P.

Curr Drug Targets. 2009 Feb;10(2):118-25. Review.

PMID:
19199907
4.

Antibody-drug conjugates targeting prostate-specific membrane antigen.

Olson WC, Israel RJ.

Front Biosci (Landmark Ed). 2014 Jan 1;19:12-33. Review.

PMID:
24389170
5.

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ.

Semin Oncol. 2003 Oct;30(5):667-76. Review.

PMID:
14571414
6.

Ketoconazole and liarozole in the treatment of advanced prostatic cancer.

Mahler C, Verhelst J, Denis L.

Cancer. 1993 Feb 1;71(3 Suppl):1068-73. Review.

7.

Immunotherapy for prostate cancer.

Fong L, Small EJ.

Semin Oncol. 2003 Oct;30(5):649-58. Review.

PMID:
14571412
8.

Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.

Price N.

Clin Prostate Cancer. 2004 Sep;3(2):77-9. Review. No abstract available.

PMID:
15479488
9.

Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI.

Curr Urol Rep. 2005 May;6(3):163-70. Review.

PMID:
15869719
10.

Management of high risk metastatic prostate cancer: the case for novel therapies.

Brand TC, Tolcher AW.

J Urol. 2006 Dec;176(6 Pt 2):S76-80; discussion S81-2. Review.

PMID:
17084174
11.

Targeting the prostate-specific membrane antigen for prostate cancer therapy.

Bühler P, Wolf P, Elsässer-Beile U.

Immunotherapy. 2009 May;1(3):471-81. doi: 10.2217/imt.09.17. Review.

PMID:
20635963
12.

Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.

Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ.

Curr Radiopharm. 2016;9(1):44-53. Review.

PMID:
25771365
13.

Targeted treatment of prostate cancer.

Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, Heston WD.

J Cell Biochem. 2007 Oct 15;102(3):571-9. Review.

PMID:
17685433
14.

[Metastatic prostate cancer treatment in the elderly].

Falandry C, Bonnefoy M, You B, Freyer G.

Bull Cancer. 2007 Jul;94(7 Suppl):F89-96. Review. French.

PMID:
17845998
15.

Bone directed therapies for prostate cancer.

Bradley DA, Hussain M, Dipaola RS, Kantoff P.

J Urol. 2007 Sep;178(3 Pt 2):S42-8. Epub 2007 Jul 20. Review.

PMID:
17644119
16.

Is prostate-specific membrane antigen a multifunctional protein?

Rajasekaran AK, Anilkumar G, Christiansen JJ.

Am J Physiol Cell Physiol. 2005 May;288(5):C975-81. Review.

17.

[Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer].

Tang QL, Yao MY.

Zhonghua Nan Ke Xue. 2008 Jan;14(1):79-82. Review. Chinese.

PMID:
18297820
18.

Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma.

Berdeja JG.

Front Biosci (Landmark Ed). 2014 Jan 1;19:163-70. Review.

PMID:
24389179
19.
20.

Bone metabolism and new targets for intervention.

Akduman B, Crawford ED.

Curr Urol Rep. 2007 May;8(3):233-8. Review.

PMID:
17459273

Supplemental Content

Support Center